Brief: Celcuity To Initiate Phase 3 Clinical Trial For Gedatolisib As First-Line Treatment For HR+/HER2- Advanced Breast Cancer
30/05/2024 12:32
May 30 (Reuters) - Celcuity Inc CELC.O :
* CELCUITY INC. ANNOUNCES PLAN TO INITIATE A PHASE 3
CLINICAL
TRIAL FOR GEDATOLISIB AS FIRST-LINE TREATMENT FOR HR+/HER2-
ADVANCED BREAST CANCER AND SECURES APPROXIMATELY $62 MILLION
DEBT FINANCING
* CELCUITY INC: RECEIVED AN ADDITIONAL TERM LOAN OF
APPROXIMATELY
$62 MILLION
* CELCUITY INC: EXPECTS TO ENROLL FIRST PATIENT IN Q2 OF
2025
Source text for Eikon: ID:nGNX4yFDg8
Further company coverage: CELC.O
((Reuters.Briefs@thomsonreuters.com;))